title: A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice.
abstract: Deregulated Rho GTPases Rac1 and Cdc42 have been discovered in various tumors, including prostate and Rac protein expression significantly increases in prostate cancer. The Rac and Cdc42 pathways promote the uncontrolled proliferation, invasion and metastatic properties of human cancer cells. We synthesized the novel compound AZA1 based on structural information of the known Rac1 inhibitor NSC23766. In the current study we investigated the effects of inhibition of these pathways by AZA1 on prostate tumorigenicity by performing preclinical studies using a xenograft mouse model of prostate cancer. In androgen-independent prostate cancer cells, AZA1 inhibited both Rac1 and Cdc42 but not RhoA GTPase activity in a dose-dependent manner and blocked cellular migration and proliferation. Cyclin D1 expression significantly decreased following Rac1/Cdc42 inhibition in prostate cancer cells. AZA1 treatment also down-regulated PAK and AKT activity in prostate cancer cells, associated with induction of the pro-apoptotic function of BAD by suppression of serine-112 phosphorylation. Daily systemic administration of AZA1 for 2 weeks reduced growth of human 22Rv1 prostate tumor xenografts in mice and improved the survival of tumor-bearing animals significantly. These data suggest a role of AZA1 in blocking Rac1/Cdc42-dependent cell cycle progression, cancer cell migration and increase of cancer cell apoptosis involving down-regulation of the AKT and PAK signaling pathway in prostate cancer cells. We therefore propose that a small-molecule inhibitor therapy targeting Rac1/Cdc42 Rho GTPase signaling pathways may be used as a novel treatment for patients with advanced prostate cancer.
authors.affiliation: Laboratory for Cardiovascular Research, Medical University of Vienna, Vienna, Austria.
authors.forename: Karin
authors.initials: K
authors.lastname: Zins
authors.forename: Trevor
authors.initials: T
authors.lastname: Lucas
authors.forename: Patrick
authors.initials: P
authors.lastname: Reichl
authors.forename: Dietmar
authors.initials: D
authors.lastname: Abraham
authors.forename: Seyedhossein
authors.initials: S
authors.lastname: Aharinejad
mesh_terms: D000199:Actins / Q000378:metabolism; D000634:Aminoquinolines / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D003599:Cytoskeleton / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D020690:GTPase-Activating Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D010750:Phosphoproteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays; D020830:rac1 GTP-Binding Protein / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: C514543:ARHGAP31 protein, human; D000199:Actins; D000634:Aminoquinolines; D000970:Antineoplastic Agents; D020690:GTPase-Activating Proteins; D007211:Indoles; C000589184:N2,N4-bis(2-methyl-1H-indol-5-yl)pyrimidine-2,4-diamine; C487513:NSC 23766; D010750:Phosphoproteins; D011743:Pyrimidines; C107953:RAC1 protein, human; D020830:rac1 GTP-Binding Protein
references.citation: Cell Mol Life Sci. 2005 May;62(10):1167-75
references.pmid: 15928809
references.citation: J Biol Chem. 1999 Sep 3;274(36):25245-9
references.pmid: 10464245
references.citation: Cell Motil Cytoskeleton. 2007 May;64(5):338-46
references.pmid: 17301947
references.citation: J Biol Chem. 2010 Aug 20;285(34):26033-40
references.pmid: 20566643
references.citation: Cell. 2003 Feb 21;112(4):453-65
references.pmid: 12600310
references.citation: Prostate. 1998 May;35(2):95-101
references.pmid: 9568672
references.citation: Clin Exp Metastasis. 2003;20(1):69-76
references.pmid: 12650609
references.citation: Science. 1995 Sep 1;269(5228):1270-2
references.pmid: 7652575
references.citation: Leukemia. 2003 Mar;17(3):590-603
references.pmid: 12646949
references.citation: Blood. 2010 Apr 22;115(16):3320-8
references.pmid: 20179179
references.citation: Cell. 1996 Nov 15;87(4):619-28
references.pmid: 8929531
references.citation: Cancer Res. 2000 Nov 1;60(21):5988-94
references.pmid: 11085518
references.citation: J Biol Chem. 2004 Jan 23;279(4):2737-46
references.pmid: 14576155
references.citation: Adv Cancer Res. 2002;84:57-80
references.pmid: 11883532
references.citation: Genes Dev. 1997 Sep 15;11(18):2295-322
references.pmid: 9308960
references.citation: Cancer Res. 2007 Feb 1;67(3):1038-45
references.pmid: 17283136
references.citation: Endocr Relat Cancer. 2007 Jun;14(2):245-56
references.pmid: 17639041
references.citation: Cell Signal. 2011 Sep;23(9):1415-23
references.pmid: 21515363
references.citation: J Cell Physiol. 2008 Dec;217(3):752-8
references.pmid: 18668521
references.citation: Mol Cell Biol. 1997 Mar;17(3):1324-35
references.pmid: 9032259
references.citation: Clin Exp Metastasis. 2010 Oct;27(7):481-91
references.pmid: 20526801
references.citation: Ann N Y Acad Sci. 2002 Nov;973:145-8
references.pmid: 12485852
references.citation: Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14477-82
references.pmid: 16973750
references.citation: Cell Cycle. 2008 Jun 15;7(12):1745-62
references.pmid: 18594202
references.citation: Endocr Relat Cancer. 2006 Mar;13(1):197-210
references.pmid: 16601288
references.citation: Cell. 1996 Nov 15;87(4):589-92
references.pmid: 8929527
references.citation: Proc Natl Acad Sci U S A. 2004 May 18;101(20):7618-23
references.pmid: 15128949
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Oncogene. 2000 Jun 15;19(26):3013-20
references.pmid: 10871853
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8146-51
references.pmid: 16278465
references.citation: FEBS Lett. 2008 Jun 18;582(14):2093-101
references.pmid: 18460342
references.citation: Mol Biol Cell. 2006 Nov;17(11):4675-85
references.pmid: 16914516
references.citation: Cell. 1997 Oct 17;91(2):231-41
references.pmid: 9346240
references.citation: Oncogene. 1998 Apr 16;16(15):1913-20
references.pmid: 9591774
references.citation: Annu Rev Biochem. 1999;68:459-86
references.pmid: 10872457
references.citation: Clin Exp Metastasis. 1996 Jan;14(1):61-72
references.pmid: 8521618
references.citation: Nat Rev Cancer. 2002 Feb;2(2):133-42
references.pmid: 12635176
references.citation: Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63
references.pmid: 19165420
references.citation: Dev Biol. 2004 Jan 1;265(1):23-32
references.pmid: 14697350
references.citation: Clin Cancer Res. 2000 May;6(5):1891-5
references.pmid: 10815912
references.citation: Biochim Biophys Acta. 2009 Dec;1796(2):91-8
references.pmid: 19327386
references.citation: Clin Transl Med. 2013 Mar 07;2(1):8
references.pmid: 23497644
references.citation: Annu Rev Cell Dev Biol. 2005;21:247-69
references.pmid: 16212495
references.citation: Biol Cell. 2008 Feb;100(2):97-108
references.pmid: 18199048
references.citation: Nature. 1995 May 25;375(6529):338-40
references.pmid: 7753201
references.citation: Clin Cancer Res. 2009 Aug 1;15(15):4799-805
references.pmid: 19638457
references.citation: Cancer Lett. 2010 May 1;291(1):1-13
references.pmid: 19717225
references.citation: Endocrinology. 2004 Dec;145(12):5439-47
references.pmid: 15331580
references.citation: Cell. 2011 Jun 24;145(7):1012-22
references.pmid: 21703446
references.citation: J Cell Sci. 1998 Jan;111 ( Pt 2):199-211
references.pmid: 9405304
references.citation: Science. 1995 Nov 24;270(5240):1326-31
references.pmid: 7481820
references.citation: J Cell Physiol. 2009 Aug;220(2):292-6
references.pmid: 19415697
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: J Clin Invest. 2011 Aug;121(8):3189-205
references.pmid: 21747164
references.citation: Nat Cell Biol. 2008 Nov;10(11):1356-64
references.pmid: 18931661
references.citation: Oncogene. 1999 Nov 18;18(48):6835-9
references.pmid: 10597294
references.citation: Clin Chem. 2008 Dec;54(12):1951-60
references.pmid: 18927246
references.citation: Cancer Res. 2002 Sep 15;62(18):5317-24
references.pmid: 12235002
references.citation: J Biol Chem. 2006 Jul 28;281(30):20891-20901
references.pmid: 16728406
references.citation: Cancer Res. 2004 Aug 1;64(15):5378-84
references.pmid: 15289345
references.citation: Oncogene. 2010 Oct 28;29(43):5839-49
references.pmid: 20711231
references.citation: Int J Cancer. 1999 May 31;81(5):682-7
references.pmid: 10328216
references.citation: Int J Cancer. 2011 Mar 15;128(6):1269-79
references.pmid: 20473940
references.citation: J Med Chem. 2009 Jul 23;52(14):4087-90
references.pmid: 19527032
references.citation: J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400
references.pmid: 11562390
references.citation: Cell Cycle. 2007 May 2;6(9):1115-21
references.pmid: 17426454